Illuminate ALSP Natural History Study
This observational, multicenter study is prospectively following patients with ALSP to understand the natural course of the disease, evaluate imaging and soluble biomarkers, and provide insights into potential endpoints and patient populations for future interventional trials. Learn more about the Illuminate ALSP study at https://alspstudy.com/.
First-In-Human Phase 1 Trial
This clinical trial is a dose escalating trial of iluzanebart (VGL101) involving single and multiple ascending doses (SAD/MAD) in healthy volunteers, including subjects of various ethnic backgrounds. This trial is designed to evaluate safety and tolerability as well as measure biomarkers to confirm target engagement. This trial will provide a foundation for clinical trials of iluzanebart in patients with ALSP as well as with other neurodegenerative disorders.
Ignite Phase 2 Trial in Patients with ALSP
This is a multicenter, open-label trial to assess the safety and tolerability of iluzanebart (VGL101) in patients with documentation of a mutation in the CSF1R gene for the treatment of ALSP and to evaluate the effects of iluzanebart on brain imaging, biomarkers and signs and symptoms of disease progression. Learn more about the Ignite trial at https://alspstudy.com or visit clinicaltrials.gov (NCT05677659).
Expanded Access Policy
Vigil Neuroscience, Inc. (“Vigil”) is dedicated to developing innovative, safe and effective therapies for rare and common neurodegenerative diseases.
Expanded Access, also referred to as Compassionate Use, is the use of an investigational therapy outside of a clinical trial. Currently, Vigil does not have an Expanded Access or Compassionate Use Program and the only way to obtain access to Vigil’s investigational therapies is to participate in a clinical trial. We may re-evaluate the status of our Expanded Access Policy as development of our therapies progresses.
We understand that for people living with neurodegenerative diseases, waiting for approved treatments is difficult. We recognize the urgency for new therapies to be developed and are steadfast in our commitment to people living with rare and common neurodegenerative diseases.
For additional information on our clinical trials or questions about our Expanded Access Policy, please contact trials@vigilneuro.com.